To help alleviate the shortage of organs, there has been an increase in the transplantation of livers obtained from extended criteria donors, such as organs from HBcAb positive and HCV positive donors. In the Pitt study, the researchers conducted a seven-year review of liver transplant recipients who received HBV positive and HCV positive organs between 1997 and 2004. The patients were divided into three groups. Group one consisted of 28 patients that received both HBcAb positive and HCV positive livers; the second group consisted of 58 patients that received HBcAb positive livers; and the third group consisted of 34 patients that received HCV positive livers. Patient and graft survival and recurrence of the HBV and HCV infections were compared between the various groups of patients.
Treatment to prevent recurrent HBV infection consisted of hepatitis B immune globulin and/or lamivudine for groups one and two. The mean follow up for all patients was two years and there were no significant differences between recipients of all groups with respect to age, sex and MELD scores a liver transplant scoring system which estimates a patient's risk of dying while waiting for the transplant.
Patient and graft survival were the following: Group one, 68 percent and 64 percent re
Contact: Maureen McGaffin or Frank Raczkiewicz
University of Pittsburgh Medical Center